• Tue news: 23andMe CEO no longer open to takeover. mRNA vaccines may boost cancer immunotherapy. BMS beats $6.4B lawsuit. CVS Health layoffs and potential breakup. JNJ abandoning proposed 340b plan. See more on our front page

CNBC reports Pfizer going to spin off pharma businesses?

Anonymous

Guest
- consumer, animal and nutritionals going to be spun off.

- pharma business going to be split up and spun off for value of parts greater than the sum total.

- Pfizer going to buy back $5-7 billion of share through repurchases.

Pfizer is going to look like an Roche/Genentech or Abbot/Humira deal in the near future as the valuation model.

Changes to be detailed in June 2011.
 

<



- consumer, animal and nutritionals going to be spun off.

- pharma business going to be split up and spun off for value of parts greater than the sum total.

- Pfizer going to buy back $5-7 billion of share through repurchases.

Pfizer is going to look like an Roche/Genentech or Abbot/Humira deal in the near future as the valuation model.

Changes to be detailed in June 2011.

Einstein where have you been. This was reported over a month ago. You are most likely in a mgmt./mket. position because you are just too plain stupid to know what is going on in your own company. How pathetic.
 




Are you for real? NOTHING new was discussed on CNBC. The only tidbit of minor interest was Barbara Ryan (Deutsche Bank)'s hypothesis on timing of new drug launches and the impact on the sale of the businesses
 












I liked this section: "Those big mergers sidetracked its researchers and salespeople and created baroque management structures—at one point there were 17 layers between the chief executive and the lowest employee." That's Pfizer alright.........
 




Einstein where have you been. This was reported over a month ago. You are most likely in a mgmt./mket. position because you are just too plain stupid to know what is going on in your own company. How pathetic.

I've been out working in the field, while you read CP and masterbate on your computer screen, numbnuts!
 








- consumer, animal and nutritionals going to be spun off.

- pharma business going to be split up and spun off for value of parts greater than the sum total.

- Pfizer going to buy back $5-7 billion of share through repurchases.

Pfizer is going to look like an Roche/Genentech or Abbot/Humira deal in the near future as the valuation model.

Changes to be detailed in June 2011.

Old news but accurate. This is the ONLY chance Pfizer has at success, given how bloated and complex the company is right now.